In response to the rapid advancements in nucleic acid therapeutics, pharmaceutical companies have forged partnerships with contract development and manufacturing organizations (CDMOs). This shift toward outsourcing, combined with the increasing demand for pharmaceuticals, has resulted in the global expansion of the nucleic acid therapeutics CDMO market. CDMOs provide a comprehensive array of services, encompassing the manufacture of active pharmaceutical ingredients, the production of drug products, final packaging, product development, and characterization.
The Asia-Pacific (APAC)region is experiencing the fastest growth as a market for nucleic acid therapeutics. Governments in the Asia-Pacific are also offering substantial assistance to foster the advancement and production of nucleic acid therapeutics.
According to the BIS Research market intelligence report, the APAC nucleic acid therapeutics CDMO market was valued at $0.97 billion in 2022 and is expected to reach $4.04 billion by 2033, growing at a CAGR of 13.92% during the forecast period 2023-2033.
The presence of established pharmaceutical players in APAC is a significant driver, promising substantial short-term and moderate long-term impact on the APAC nucleic acid therapeutics CDMO market. Government funding and support are expected to continue playing a vital role in encouraging research and development. Moreover, APAC's relatively low manufacturing costs are set to attract pharmaceutical companies, making it a driver for the APAC nucleic acid therapeutics CDMO market.
Opportunities lie in the global expansion of the market as outsourcing gains traction, resulting in partnerships and collaborations. The diverse services offered by APAC CDMOs provide a range of expertise to pharmaceutical companies.
However, the high cost of synthesized oligonucleotides and a shortage of skilled professionals are expected to restrain the growth of the nucleic acid therapeutics CDMO market.
BIS Research report on the APAC nucleic acid therapeutics market is segmented by chemical synthesis methods and countries. The solid-phase oligonucleotide synthesis (SPOS) category dominated the chemical synthesis methods market segment in 2022, and this trend is expected to persist from 2023 to 2033. Moreover, the liquid-phase oligonucleotide synthesis (LPOS) segment is foreseen to exhibit substantial growth, with a projected compound annual growth rate (CAGR) of 18.43% throughout the forecast period.
China claimed the largest market share in the region in 2022, and this pattern is anticipated to endure throughout the forecast period spanning from 2022 to 2033.
Two key trends are shaping the nucleic acid therapeutics CDMO market. Firstly, there is a significant increase in investment for expanding CDMO manufacturing units to meet growing demand. This involves acquiring new facilities, upgrading existing ones, and adopting advanced technologies for enhanced efficiency.
CDMOs are shifting their business strategy from traditional manufacturing roles to more innovative and diversified services. They're investing in new facilities to support emerging therapeutic modalities and adapting to accommodate smaller, diverse projects. This transformation is driven by partnerships and acquisitions, enabling CDMOs to play a more substantial role in the pharmaceutical industry's evolution, particularly in areas like vaccine production.
The APAC nucleic acid therapeutics CDMO market report offers unique selling points (USPs), such as an in-depth competitive analysis of major players, providing a comprehensive overview of the APAC nucleic acid therapeutics CDMO market. It examines the market's economic influence and highlights notable end-user industry advancements. The report conducts a thorough supply chain and pricing analysis. It also delves into the investment landscape, assessing product adoption trends and patents. These features make the report a valuable resource for understanding the APAC nucleic acid therapeutics CDMO market's dynamics and opportunities.
BIS principal analyst from healthcare says, "In addition to traditional business models, CDMOs are now exploring fresh and inventive approaches. They are transitioning towards a comprehensive "one-stop-shop" service model within the CDMO value chain. These novel models emphasize addressing CDMOs' manufacturing deficiencies and are particularly dedicated to developing their drug portfolios."
Interested to know more about the growing technologies in your industry vertical? Get the latest market studies and insights from BIS Research. Connect with us at [email protected] to learn and understand more.
